Creative Planning reduced its stake in Clovis Oncology, Inc. (NASDAQ:CLVS) by 3.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 62,382 shares of the biopharmaceutical company’s stock after selling 2,462 shares during the quarter. Creative Planning’s holdings in Clovis Oncology were worth $4,242,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. PNC Financial Services Group Inc. lifted its holdings in Clovis Oncology by 0.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,820 shares of the biopharmaceutical company’s stock worth $265,000 after buying an additional 20 shares in the last quarter. Hanseatic Management Services Inc. lifted its holdings in Clovis Oncology by 0.3% during the 2nd quarter. Hanseatic Management Services Inc. now owns 13,693 shares of the biopharmaceutical company’s stock worth $1,282,000 after buying an additional 37 shares in the last quarter. Amalgamated Bank lifted its holdings in Clovis Oncology by 10.4% during the 2nd quarter. Amalgamated Bank now owns 4,811 shares of the biopharmaceutical company’s stock worth $450,000 after buying an additional 454 shares in the last quarter. Prudential Financial Inc. lifted its holdings in Clovis Oncology by 15.5% during the 2nd quarter. Prudential Financial Inc. now owns 4,388 shares of the biopharmaceutical company’s stock worth $411,000 after buying an additional 590 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Clovis Oncology by 21.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,725 shares of the biopharmaceutical company’s stock valued at $349,000 after purchasing an additional 655 shares in the last quarter.
In other Clovis Oncology news, Director Thorlef Spickschen sold 4,500 shares of the firm’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $64.97, for a total transaction of $292,365.00. Following the transaction, the director now directly owns 21,118 shares of the company’s stock, valued at approximately $1,372,036.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $59.16, for a total transaction of $177,480.00. Following the transaction, the insider now directly owns 183,571 shares in the company, valued at $10,860,060.36. The disclosure for this sale can be found here. Insiders sold a total of 18,000 shares of company stock worth $1,123,425 over the last ninety days. Insiders own 12.50% of the company’s stock.
Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.06). The company had revenue of $16.81 million during the quarter, compared to analysts’ expectations of $21.12 million. Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. During the same period last year, the business earned ($1.70) earnings per share. research analysts predict that Clovis Oncology, Inc. will post -7.65 earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on the stock. Morgan Stanley reduced their price objective on shares of Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating on the stock in a report on Thursday, November 2nd. BidaskClub lowered shares of Clovis Oncology from a “sell” rating to a “strong sell” rating in a report on Friday. Oppenheimer restated a “hold” rating on shares of Clovis Oncology in a report on Wednesday, December 20th. ValuEngine upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $125.00 price objective on shares of Clovis Oncology in a report on Friday, November 3rd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company’s stock. Clovis Oncology currently has an average rating of “Hold” and an average price target of $90.43.
Clovis Oncology Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology, Inc. (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.